Madrigal Pharmaceuticals
Madrigal Pharmaceuticals' revenue rose 432.1% to $958 million in fiscal 2025. Its operating margin was −31.3%, up from −276.4% a year earlier. Free cash flow was −$190 million. The diluted share count rose 5.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Madrigal Pharmaceuticals lost money in fiscal 2025: a net loss of $288 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 270 | 359 | 634 | 931 | 984 |
| Debt incl. finance leases | 0 | 70 | 116 | 118 | 340 |
| Net debt (negative means net cash) | −270 | −289 | −519 | −814 | −644 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.3x | 0.3x | 0.2x | 0.6x |
| Interest coverage | — | −74.1x | −29.9x | −33.9x | −13.4x |
| Current ratio | 3.5x | 3.1x | 5.4x | 6.1x | 4.0x |
| Quick ratio | 3.5x | 3.1x | 5.4x | 5.9x | 3.8x |
Cash flow
Projections
Project Madrigal Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Madrigal Pharmaceuticals shares on the open market, and 8 insiders sold $69.0 million, $61.5 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | William John SiboldPresident and CEO, Director | Sold plan | 5,221 | $542.38 | $2.8 million | Form 4 |
| Sep 9, 2026 | William John SiboldPresident and CEO, Director | Sold plan | 6,362 | $535.59 | $3.4 million | Form 4 |
| Aug 17, 2026 | Shannon T KelleyGeneral Counsel | Sold | 664 | $514.97 | $341,940 | Form 4 |
| Jul 20, 2026 | William John SiboldPresident and CEO, Director | Sold | 2,500 | $547.30 | $1.4 million | Form 4 |
| Jun 1, 2026 | David SoergelChief Medical Officer | Sold plan | 1,042 | $495.74 | $516,561 | Form 4 |
| May 22, 2026 | Richard S LevyDirector | Sold plan | 5,682 | $515.44 | $2.9 million | Form 4 |
| May 18, 2026 | David SoergelChief Medical Officer | Sold | 844 | $515.90 | $435,420 | Form 4 |
| Mar 6, 2026 | Mardi DierEVP and CFO | Sold plan | 1,982 | $430.87 | $853,993 | Form 4 |
| Mar 6, 2026 | William John SiboldPresident and CEO, Director | Sold | 1,663 | $431.94 | $718,316 | Form 4 |
| Mar 6, 2026 | Rebecca TaubDirector | Sold | 491 | $431.94 | $212,083 | Form 4 |
| Mar 6, 2026 | Carole HuntsmanChief Commercial Officer | Sold | 419 | $431.94 | $180,983 | Form 4 |
| Mar 6, 2026 | Shannon T KelleyGeneral Counsel | Sold | 360 | $431.94 | $155,498 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 8 | 5 of 8 | 3 of 8 |
| Rule of 40 | — | — | 412.2% |
| Altman Z'' | −3.67 | −0.66 | −1.18 |
| Accruals ratio | −9.8% | −1.2% | −8.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 3 of 8 | 5 of 8 | 3 of 8 |
Compare
Put Madrigal Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | FY25 | 432.1% | −31.3% | −19.8% | — | — | 3 | |
| Ionis Pharmaceuticals | FY25 | 33.8% | −40.5% | −33.9% | — | — | 3 | Compare |
| Tilray Brands | FY26 | 11.5% | −6.9% | — | −3.4% | — | 3 | Compare |
| ANI Pharmaceuticals | FY25 | 43.8% | 12.6% | 19.4% | 15.9% | 0.1x | 6 | Compare |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 180 | 958 |
| Revenue growth | — | — | — | — | — | — | — | — | — | 432.1% |
| Gross profit | — | — | — | — | — | — | 0 | 0 | 174 | — |
| Research and development | 16 | 24 | 25 | 72 | 185 | 205 | 245 | 272 | 237 | 388 |
| Operating income | −25 | −32 | −41 | −95 | −207 | −242 | −294 | −380 | −498 | −300 |
| Net income | −26 | −31 | −33 | −84 | −202 | −242 | −295 | −374 | −466 | −288 |
| Diluted EPS (US$) | −5.07 | −2.54 | −2.22 | −5.45 | −13.09 | −14.63 | −17.23 | −19.99 | −21.90 | −12.85 |
| Diluted shares (millions) | 5 | 12 | 15 | 15 | 15 | 16 | 17 | 19 | 21 | 22 |
| Cash flow | ||||||||||
| Cash from operations | −18 | −22 | −26 | −42 | −158 | −184 | −225 | −324 | −456 | −190 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 |
| Free cash flow | −18 | −22 | −26 | −42 | −158 | −184 | −225 | −326 | −457 | −190 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 8 | 3 | 14 | 23 | 21 | 27 | 32 | 50 | 80 | 98 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 19 | 192 | 484 | 439 | 284 | 270 | 359 | 634 | 931 | 984 |
| Debt incl. finance leases | — | — | — | — | — | 0 | 70 | 116 | 118 | 340 |
| Total assets | 41 | 192 | 485 | 442 | 287 | 273 | 363 | 640 | 1,042 | 1,260 |
| Total liabilities | 5 | 10 | 8 | 26 | 47 | 77 | 165 | 235 | 288 | 657 |
| Shareholders' equity | 36 | 182 | 477 | 417 | 240 | 196 | 197 | 405 | 754 | 603 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | 96.5% | — |
| Operating margin | — | — | — | — | — | — | — | — | −276.4% | −31.3% |
| Net margin | — | — | — | — | — | — | — | — | −258.6% | −30.1% |
| Free cash flow margin | — | — | — | — | — | — | — | — | −253.7% | −19.8% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | — | 412.2% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | −28.5% | −9.9% | −18.8% | −61.6% | −110.9% | −150.1% | −124.0% | −80.3% | −42.5% |
| Return on assets | −127.0% | −26.7% | −9.7% | −18.1% | −55.5% | −86.3% | −92.9% | −74.5% | −55.4% | −25.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |